Cargando…

Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy

Aims: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumor residue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assess the predictive capac...

Descripción completa

Detalles Bibliográficos
Autores principales: Brenet, Esteban, Barbe, Coralie, Hoeffel, Christine, Dubernard, Xavier, Merol, Jean-Claude, Fath, Léa, Servagi-Vernat, Stéphanie, Labrousse, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281260/
https://www.ncbi.nlm.nih.gov/pubmed/32422975
http://dx.doi.org/10.3390/cancers12051234
_version_ 1783543881638346752
author Brenet, Esteban
Barbe, Coralie
Hoeffel, Christine
Dubernard, Xavier
Merol, Jean-Claude
Fath, Léa
Servagi-Vernat, Stéphanie
Labrousse, Marc
author_facet Brenet, Esteban
Barbe, Coralie
Hoeffel, Christine
Dubernard, Xavier
Merol, Jean-Claude
Fath, Léa
Servagi-Vernat, Stéphanie
Labrousse, Marc
author_sort Brenet, Esteban
collection PubMed
description Aims: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumor residue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assess the predictive capacity of pre-treatment diffusion-weighted MRI for persistent tumor residue post-CRT. Materials and Method: A single center cohort study was performed in one French hospital. All patients with squamous cell carcinoma receiving CRT (no surgical indication) were included. Two diffusion-weighted MRI were performed: one within 8 days before CRT and one 3 months after completing CRT with determination of median tumor apparent diffusion coefficient (ADC). Main outcome: The primary endpoint was progression-free survival. Results: 59 patients were included prior to CRT and 46 (78.0%) completed CRT. A post-CRT tumor residue was found in 19/46 (41.3%) patients. In univariate analysis, initial ADC was significantly lower in patients with residue post CRT (0.56 ± 0.11 versus 0.79 ± 0.13; p < 0.001). When initial ADC was dichotomized at the median, initial ADC lower than 0.7 was significantly more frequent in patients with residue post CRT (73.7% versus 11.1%, p < 0.0001). In multivariate analysis, only initial ADC lower than 0.7 was significantly associated with tumor residue (OR = 22.6; IC [4.9–103.6], p < 0.0001). Among 26 patients without tumor residue after CRT and followed up until 12 months, 6 (23.1%) presented recurrence or progression. Only univariate analysis was performed due to a small number of events. The only factor significantly associated with disease progression or early recurrence was the delta ADC (p = 0.0009). When ADC variation was dichotomized at the median, patients with ADC variation greater than 0.7 had time of disease-free survival significantly longer than patients with ADC variation lower than 0.7 (377.5 [286–402] days versus 253 [198–370], p < 0.0001). Conclusion and relevance: Diffusion-weighted MRI could be a technique that enables differentiation of patients with high potential for early recurrence for whom intensive post-CRT monitoring is mandatory. Prospective studies with more inclusions would be necessary to validate our results.
format Online
Article
Text
id pubmed-7281260
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72812602020-06-15 Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy Brenet, Esteban Barbe, Coralie Hoeffel, Christine Dubernard, Xavier Merol, Jean-Claude Fath, Léa Servagi-Vernat, Stéphanie Labrousse, Marc Cancers (Basel) Article Aims: To investigate the predictive capacity of early post-treatment diffusion-weighted magnetic resonance imaging (MRI) for recurrence or tumor progression in patients with no tumor residue after chemo-radiotherapy (CRT) for head and neck squamous cell carcinoma, and, to assess the predictive capacity of pre-treatment diffusion-weighted MRI for persistent tumor residue post-CRT. Materials and Method: A single center cohort study was performed in one French hospital. All patients with squamous cell carcinoma receiving CRT (no surgical indication) were included. Two diffusion-weighted MRI were performed: one within 8 days before CRT and one 3 months after completing CRT with determination of median tumor apparent diffusion coefficient (ADC). Main outcome: The primary endpoint was progression-free survival. Results: 59 patients were included prior to CRT and 46 (78.0%) completed CRT. A post-CRT tumor residue was found in 19/46 (41.3%) patients. In univariate analysis, initial ADC was significantly lower in patients with residue post CRT (0.56 ± 0.11 versus 0.79 ± 0.13; p < 0.001). When initial ADC was dichotomized at the median, initial ADC lower than 0.7 was significantly more frequent in patients with residue post CRT (73.7% versus 11.1%, p < 0.0001). In multivariate analysis, only initial ADC lower than 0.7 was significantly associated with tumor residue (OR = 22.6; IC [4.9–103.6], p < 0.0001). Among 26 patients without tumor residue after CRT and followed up until 12 months, 6 (23.1%) presented recurrence or progression. Only univariate analysis was performed due to a small number of events. The only factor significantly associated with disease progression or early recurrence was the delta ADC (p = 0.0009). When ADC variation was dichotomized at the median, patients with ADC variation greater than 0.7 had time of disease-free survival significantly longer than patients with ADC variation lower than 0.7 (377.5 [286–402] days versus 253 [198–370], p < 0.0001). Conclusion and relevance: Diffusion-weighted MRI could be a technique that enables differentiation of patients with high potential for early recurrence for whom intensive post-CRT monitoring is mandatory. Prospective studies with more inclusions would be necessary to validate our results. MDPI 2020-05-14 /pmc/articles/PMC7281260/ /pubmed/32422975 http://dx.doi.org/10.3390/cancers12051234 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Brenet, Esteban
Barbe, Coralie
Hoeffel, Christine
Dubernard, Xavier
Merol, Jean-Claude
Fath, Léa
Servagi-Vernat, Stéphanie
Labrousse, Marc
Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title_full Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title_fullStr Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title_full_unstemmed Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title_short Predictive Value of Early Post-Treatment Diffusion-Weighted MRI for Recurrence or Tumor Progression of Head and Neck Squamous Cell Carcinoma Treated with Chemo-Radiotherapy
title_sort predictive value of early post-treatment diffusion-weighted mri for recurrence or tumor progression of head and neck squamous cell carcinoma treated with chemo-radiotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281260/
https://www.ncbi.nlm.nih.gov/pubmed/32422975
http://dx.doi.org/10.3390/cancers12051234
work_keys_str_mv AT brenetesteban predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT barbecoralie predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT hoeffelchristine predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT dubernardxavier predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT meroljeanclaude predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT fathlea predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT servagivernatstephanie predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy
AT labroussemarc predictivevalueofearlyposttreatmentdiffusionweightedmriforrecurrenceortumorprogressionofheadandnecksquamouscellcarcinomatreatedwithchemoradiotherapy